150 related articles for article (PubMed ID: 29104287)
1. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.
Molenaar RJ; Pleyer C; Radivoyevitch T; Sidana S; Godley A; Advani AS; Gerds AT; Carraway HE; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Angelini D; Maciejewski JP; Majhail N; Sekeres MA; Mukherjee S
Leukemia; 2018 Apr; 32(4):952-959. PubMed ID: 29104287
[TBL] [Abstract][Full Text] [Related]
2. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer.
Molenaar RJ; Sidana S; Radivoyevitch T; Advani AS; Gerds AT; Carraway HE; Angelini D; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Maciejewski JP; Majhail NS; Sekeres MA; Mukherjee S
J Clin Oncol; 2018 Jun; 36(18):1831-1839. PubMed ID: 29252123
[TBL] [Abstract][Full Text] [Related]
3. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.
Marti JL; Jain KS; Morris LG
Thyroid; 2015 Jun; 25(6):681-7. PubMed ID: 25851829
[TBL] [Abstract][Full Text] [Related]
4. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.
Iyer NG; Morris LG; Tuttle RM; Shaha AR; Ganly I
Cancer; 2011 Oct; 117(19):4439-46. PubMed ID: 21432843
[TBL] [Abstract][Full Text] [Related]
5. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role?
Silva-Vieira M; Carrilho Vaz S; Esteves S; Ferreira TC; Limbert E; Salgado L; Leite V
Thyroid; 2017 Aug; 27(8):1068-1076. PubMed ID: 28614983
[TBL] [Abstract][Full Text] [Related]
6. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent or Persistent Well-Differentiated Thyroid Cancer.
Chinn SB; Zafereo ME; Waguespack SG; Edeiken BS; Roberts DB; Clayman GL
Thyroid; 2017 Oct; 27(10):1291-1299. PubMed ID: 28806882
[TBL] [Abstract][Full Text] [Related]
8. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
9. Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review.
Ali Hailan YM; Al-Dubai HN; Yassin MA
Oncology; 2023; 101(6):362-368. PubMed ID: 37231874
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
11. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
12. Management and outcome of recurrent well-differentiated thyroid carcinoma.
Palme CE; Waseem Z; Raza SN; Eski S; Walfish P; Freeman JL
Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):819-24. PubMed ID: 15262757
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.
Wreesmann VB; Nixon IJ; Rivera M; Katabi N; Palmer F; Ganly I; Shaha AR; Tuttle RM; Shah JP; Patel SG; Ghossein RA
Thyroid; 2015 May; 25(5):503-8. PubMed ID: 25748079
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing radioiodine uptake after thyroid cancer surgery.
Bai JB; Shakerian R; Westcott JD; Lichtenstein M; Miller JA
ANZ J Surg; 2015; 85(7-8):572-7. PubMed ID: 23964714
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
16. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
17. Frequency of High-Risk Characteristics Requiring Total Thyroidectomy for 1-4 cm Well-Differentiated Thyroid Cancer.
Kluijfhout WP; Pasternak JD; Lim J; Kwon JS; Vriens MR; Clark OH; Shen WT; Gosnell JE; Suh I; Duh QY
Thyroid; 2016 Jun; 26(6):820-4. PubMed ID: 27083216
[TBL] [Abstract][Full Text] [Related]
18. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?
Kiernan CM; Parikh AA; Parks LL; Solórzano CC
J Am Coll Surg; 2015 Apr; 220(4):617-25. PubMed ID: 25667136
[TBL] [Abstract][Full Text] [Related]
19. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
[TBL] [Abstract][Full Text] [Related]
20. Quality of life impact of external beam radiotherapy for advanced thyroid carcinoma.
Gal TJ; Streeter M; Burris J; Kudrimoti M; Ain KB; Valentino J
Thyroid; 2013 Jan; 23(1):64-9. PubMed ID: 22971127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
